24/7 Market News Snapshot 16 October, 2025 – BIOMERICA INC (NASDAQ:BMRA)

October 16, 2025

DENVER, Colo., 16 October, 2025 (www.247marketnews.com) – (Nasdaq:BMRA) are discussed in this article.
Biomerica Inc. (Nasdaq:BMRA) is demonstrating a significant upward momentum, trading at $3.186, which represents an 11.40% increase from the previous close of $2.860. This surge is accompanied by a considerable trading volume of 2.22 million shares, reflecting heightened investor interest and optimism regarding the company’s prospects. The stock’s strong performance indicates potential for continued upward movement, with key support levels aligning near the previous close and resistance levels likely forming around recent highs. Investors are advised to keep a close watch for breakout patterns and volume trends that could further highlight BMRA’s bullish potential.

Adding to this positive outlook, Biomerica has entered into a strategic marketing collaboration with Henry Schein, Inc. (Nasdaq:HSIC), a leader in health care solutions. This partnership aims to enhance the accessibility of Biomerica’s innovative inFoods® Irritable Bowel Syndrome (IBS) test throughout the United States, representing a significant step in Biomerica’s mission to improve patient care in gastrointestinal health.

Henry Schein will utilize its robust nationwide distribution network, supported by over 400 sales representatives, to promote the inFoods® IBS test within primary care and gastroenterology settings. With nearly 100 years of industry experience and extensive annual sales exceeding $12 billion, Henry Schein is well-equipped to facilitate the growth and adoption of this groundbreaking diagnostic tool.

Zack Irani, Biomerica’s CEO, expressed excitement about the collaboration, citing the alignment of both companies’ commitment to innovative healthcare solutions. The inFoods® IBS test employs a straightforward finger-stick blood sample to identify specific food triggers that exacerbate IBS symptoms, providing patients with a personalized, non-drug therapeutic option. Given that IBS affects approximately 10% to 15% of adults, this partnership is poised to set new standards in the management and treatment of IBS, ultimately enhancing the quality of care for countless individuals.

Related news for (BMRA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.